Dr. Harris on Controversy of PSA Testing for Prostate Cancer

Richard Harris, MD
Published: Friday, Jan 20, 2017



Richard Harris, MD, urologist, UroPartners, discusses PSA testing for patients with prostate cancer and the controversial grade D recommendation of the United States Task Force.

There were no urologists, medical oncologists, or radiologists on the US task force panel, Harris explains. The issue that everyone understands is not whether or not PSA testing should be performed, but if you should have a biopsy and find prostate cancer, what the next course of action is.

PSA testing is the main method for early detection of prostate cancer, explains Harris. There are going to be 180,000 to 200,000 newly diagnosed cases this year, making PSA testing an extremely important tool for early detection.



Richard Harris, MD, urologist, UroPartners, discusses PSA testing for patients with prostate cancer and the controversial grade D recommendation of the United States Task Force.

There were no urologists, medical oncologists, or radiologists on the US task force panel, Harris explains. The issue that everyone understands is not whether or not PSA testing should be performed, but if you should have a biopsy and find prostate cancer, what the next course of action is.

PSA testing is the main method for early detection of prostate cancer, explains Harris. There are going to be 180,000 to 200,000 newly diagnosed cases this year, making PSA testing an extremely important tool for early detection.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x